These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 226672)

  • 21. Relative potencies of dipyridamole and related agents as inhibitors of cyclic nucleotide phosphodiesterases: possible explanation of mechansim of inhibition of platelet function.
    McElroy FA; Philip RB
    Life Sci; 1975 Nov; 17(9):1479-93. PubMed ID: 173959
    [No Abstract]   [Full Text] [Related]  

  • 22. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
    Maurice DH; Haslam RJ
    Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
    Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
    Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclic GMP binding and phosphodiesterase: implication for platelet function.
    Hamet P; Coquil JF; Bousseau-Lafortune S; Franks DJ; Tremblay J
    Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():119-36. PubMed ID: 6202123
    [No Abstract]   [Full Text] [Related]  

  • 25. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from the cytosol of human platelets.
    Grant PG; Mannarino AF; Colman RW
    Thromb Res; 1990 Jul; 59(1):105-19. PubMed ID: 2169075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.
    Sudo T; Tachibana K; Toga K; Tochizawa S; Inoue Y; Kimura Y; Hidaka H
    Biochem Pharmacol; 2000 Feb; 59(4):347-56. PubMed ID: 10644042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclic nucleotide phosphodiesterase inhibition by a benzoic acid derivative.
    Killackey JJ; Killackey BA; Philp RB
    Agents Actions; 1985 Dec; 17(2):192-6. PubMed ID: 2420162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do conventional plasma cyclic nucleotide phosphodiesterase inhibitors really work in all situations?
    Wood PJ; Pao G; Ross G; Smith C
    Clin Chim Acta; 1981 Sep; 115(3):405-8. PubMed ID: 6271425
    [No Abstract]   [Full Text] [Related]  

  • 29. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
    Hoet B; Arnout J; Deckmyn H; Vermylen J
    Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
    Weishaar RE; Cain MH; Bristol JA
    J Med Chem; 1985 May; 28(5):537-45. PubMed ID: 2985781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
    Liao CH; Tzeng CC; Teng CM
    Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
    Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
    Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 34. The effect of diamide on cyclic AMP levels and cyclic nucleotide phosphodiesterase in human peripheral blood lymphocytes.
    Wedner HJ
    Biochim Biophys Acta; 1980 Apr; 628(4):407-18. PubMed ID: 6245710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet cyclic 3':5'-nucleotide phosphodiesterase released by thrombin and calcium ionophore.
    Hidaka H; Asano T
    J Biol Chem; 1976 Dec; 251(23):7508-16. PubMed ID: 187590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple molecular forms of phosphodiesterase and the regulation of cardiac muscle contractility.
    Weishaar RE; Kobylarz-Singer DC; Quade MM; Steffen RP; Kaplan HR
    J Cyclic Nucleotide Protein Phosphor Res; 1986-1987; 11(7):513-27. PubMed ID: 2831259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological inhibition of calmodulin-sensitive phosphodiesterases.
    Ilien B; Ruckstuhl M; Landry Y
    J Pharmacol; 1982; 13(2):307-16. PubMed ID: 6285085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
    Marcoz P; Prigent AF; Lagarde M; Nemoz G
    Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets.
    Lam SC; Guccione MA; Packham MA; Mustard JF
    Thromb Haemost; 1982 Apr; 47(2):90-5. PubMed ID: 6285543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
    Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
    Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.